These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402 [TBL] [Abstract][Full Text] [Related]
27. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma. Little B; Young M; Ho KJ Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831 [TBL] [Abstract][Full Text] [Related]
28. [The role of immunotherapy in metastatic cancer of the kidney]. Thiounn N J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669 [TBL] [Abstract][Full Text] [Related]
30. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198 [TBL] [Abstract][Full Text] [Related]
31. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. Whiteside TL In Vivo; 1991; 5(6):553-9. PubMed ID: 1810438 [TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Taneja SS; Pierce W; Figlin R; Belldegrun A Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023 [No Abstract] [Full Text] [Related]
33. Biologic response modifiers in the therapy of metastatic renal cell carcinoma. Quesada JR Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256 [No Abstract] [Full Text] [Related]
34. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Schendel DJ; Gansbacher B Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731 [TBL] [Abstract][Full Text] [Related]
35. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity. Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387 [TBL] [Abstract][Full Text] [Related]
36. The role of adoptive immunotherapy in solid cancers. Kruit WH; Stoter G Neth J Med; 1997 Feb; 50(2):47-68. PubMed ID: 9050332 [No Abstract] [Full Text] [Related]
37. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502 [TBL] [Abstract][Full Text] [Related]
38. The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon. Hum Gene Ther; 1992 Aug; 3(4):411-30. PubMed ID: 1326336 [No Abstract] [Full Text] [Related]
39. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells. Thompson JA; Benyunes MC; Bianco JA; Fefer A Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692 [No Abstract] [Full Text] [Related]
40. [Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2]. Usui A Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1058-64. PubMed ID: 2214469 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]